Date: 2015-11-04
Type of information: Opening of new premises
Compound:
Company: Spark Therapeutics (USA - PA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On November 4, 2015, Spark Therapeutics announced that it has expanded into the greater Boston area, where the company has opened a new satellite office. With Spark’s corporate and research headquarters remaining in west Philadelphia, the company has opened an office at 1000 Winter Street in Waltham, to support the growth of several departments, including the commercial, medical, patient advocacy and business development groups.
Spark Therapeutics is a gene therapy company. Its most advanced product candidate, SPK-RPE65, has
received both breakthrough therapy and orphan product designation and the company recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions.
Financial terms:
Latest news:
